Biologics such as anti-Tumor Necrosis Factor or TNF inhibitor (TNFi) for treatment of
Psoriatic Arthritis (PsA) has greatly reduced bone damage. This collaborative study will
provide insights into key mechanisms that underlie inflammatory arthritis and bone damage in
psoriatic joints and will catalyze biomarker discovery, identifying early biologic responders
to facilitate optimization of therapy.